Clinical trial
A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With…
NCT00096928 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00096928 |
|---|---|
| Title | A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE) |
| Official title | Raptiva Epidemiologic Study of Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE) |
| Acronym | RESPONSE |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Psoriasis |
| Enrollment | 1,846 |
| Start date | Mar 1, 2005 |
| Completion | Oct 1, 2009 |
| First posted | Nov 18, 2004 |
| Last update posted | Jul 2, 2015 |
| Countries | United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: